Two recent Japanese trials confirmed that EGFR mutation status is a predictive factor for response to EGFR-TKI treatment with a progression free survival of 10 months [31,32] and this finding paves the way for the personalized therapy for NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.